NEW YORK: BioNTech and Pfizer have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants, which also allows for the enrollment of new populations. Enrollment in the trial has been proceeding as planned and the…